Glycogen for lysosome-targeted CpG ODNs delivery and enhanced cancer immunotherapy.

Zhang, Huijie; Lai, Li; Wang, Zhiqing; Zhang, Jiawen; Zhou, Jianzhu; Nie, Yao; Chen, Jinghua

Zhang, Huijie; Lai, Li; Wang, Zhiqing; Zhang, Jiawen; Zhou, Jianzhu; Nie, Yao; Chen, Jinghua.

Afiliación

Zhang H; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China. Electronic address: zhj0502@jiangnan.edu.cn.
Lai L; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Wang Z; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Zhang J; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Zhou J; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Nie Y; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Chen J; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China. Electronic address: chenjinghua@jiangnan.edu.cn.

Int J Biol Macromol ; 257(Pt 1): 128536, 2024 Feb.

Article en En | MEDLINE | ID: mdl-38061522

Asunto(s)

Adyuvantes Inmunológicos; Neoplasias; Humanos; Adyuvantes Inmunológicos/farmacología; Oligodesoxirribonucleótidos/farmacología; Oligodesoxirribonucleótidos/química; Lisosomas; Inmunoterapia; Neoplasias/tratamiento farmacológico

Palabras clave

CpG ODNs; Drug delivery; Glycogen; Nanocarrier; cancer immunotherapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adyuvantes Inmunológicos / Neoplasias Límite: Humans Idioma: En Revista: Int J Biol Macromol Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google